These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Mojica G; Hariprasad SM; Jager RD; Mieler WF Br J Ophthalmol; 2008 Apr; 92(4):584. PubMed ID: 18369083 [No Abstract] [Full Text] [Related]
14. MS drug back on market under restricted program. FDA Consum; 2006; 40(4):7. PubMed ID: 17243280 [No Abstract] [Full Text] [Related]
15. The perilous pathway from laboratory to patient. Davidson SN Healthc Forum J; 1996; 39(4):16-9. PubMed ID: 10158754 [No Abstract] [Full Text] [Related]
16. Judge tries to broker treatment deal for patients with macular degeneration in funding row. Dyer C BMJ; 2008 Jul; 337():a864. PubMed ID: 18632681 [No Abstract] [Full Text] [Related]
17. Monoclonal antibodies: production, uses and side effects. Cowden J; Parker SK Pediatr Infect Dis J; 2006 Jun; 25(6):553-5. PubMed ID: 16732156 [No Abstract] [Full Text] [Related]
18. US drug approval ignores science's subtleties, experts say. Waltz E Nat Med; 2006 Apr; 12(4):373. PubMed ID: 16598269 [No Abstract] [Full Text] [Related]
19. Ranibizumab. Narayanan R; Kuppermann BD; Jones C; Kirkpatrick P Nat Rev Drug Discov; 2006 Oct; 5(10):815-6. PubMed ID: 17078173 [No Abstract] [Full Text] [Related]
20. [Promising treatment of neovascular age-related macular degeneration is coming. But to what price?]. Frennesson C Lakartidningen; 2007 Feb 14-20; 104(7):486-7. PubMed ID: 17375677 [No Abstract] [Full Text] [Related] [Next] [New Search]